Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel, and Wellesta Holdings, a Singapore headquartered company providing marketing and commercialization support to the healthcare sector in South East Asia, India & partnering in MENA (Middle East & North Africa), have announced an important new agreement for the marketing and distribution of the Butterfly iQ+ point-of-care ultrasound device in India. 

As part of its new agreement with Abdul Latif Jameel Health, Wellesta will register Butterfly iQ+ in India and start promoting and selling the product in the country in the fourth quarter of 2022, bringing this technology to a potential 1.2 million registered physicians in the country.

This new collaboration will offer greater distribution of Butterfly iQ+ to physicians in India thereby expanding the capabilities of the practitioners in making informed decisions thereby accelerating access to modern medical care for those who need it most. 

Butterfly iQ+ is revolutionizing medical imaging. It is a hand-held 4 in 1 single probe whole-body innovative point-of-care ultrasound device powered by the world’s only Ultrasound–on-Chip technology. 

Hailed as potentially the ‘stethoscope of the future’, the Butterfly iQ+ transforms what can sometimes be complex processes, into one connected and integrated point-of-care ultrasound (POCUS) system to help collect advanced imaging, perform rapid assessments, and guide critical procedures. It allows the sharing of results seamlessly with doctors across the globe to help read and interpret scans.